Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients.
Wang T, Navenot JM, Rafail S, Kurtis C, Carroll M, Van Kerckhoven M, Van Rossom S, Schats K, Avraam K, Broad R, Howe K, Liddle A, Clayton A, Wang R, Quinn L, Sanderson JP, McAlpine C, Carozza C, Pimpinella E, Hsu S, Brophy F, Elefant E, Bayer P, Williams D, Butler MO, Clarke JM, Gainor JF, Govindan R, Moreno V, Johnson M, Tu J, Hong DS, Blumenschein GR Jr.
Wang T, et al. Among authors: quinn l.
Mol Ther Methods Clin Dev. 2024 May 14;32(2):101265. doi: 10.1016/j.omtm.2024.101265. eCollection 2024 Jun 13.
Mol Ther Methods Clin Dev. 2024.
PMID: 38872830
Free PMC article.